Oncogenic K-Ras Activates p38 to Maintain Colorectal Cancer Cell Proliferation during MEK Inhibition
Background: Colon carcinomas frequently contain activating mutations in the K-ras proto-oncogene. K-ras itself is a poor drug target and drug development efforts have mostly focused on components of the classical Ras-activated MEK/ERK pathway. Here we have studied whether endogenous oncogenic K-ras...
Saved in:
| Main Authors: | Winan J. van Houdt, Menno T. de Bruijn, Benjamin L. Emmink, Danielle Raats, Frederik J. H. Hoogwater, Inne H. M. Borel Rinkes, Onno Kranenburg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Cellular Oncology |
| Online Access: | http://dx.doi.org/10.3233/CLO-2010-0521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resistance to MAPK Pathway Inhibition in <i>BRAF</i>-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors
by: Layla El Bouazzaoui, et al.
Published: (2025-06-01) -
Differential Notch and TGFβ Signaling in Primary Colorectal Tumors and Their Corresponding Metastases
by: Liesbeth M. Veenendaal, et al.
Published: (2008-01-01) -
BRAFV600E maintains the CpG island methylator phenotype, and DNA methylation of PRC2 targets genes in colon cancer
by: Layla El Bouazzaoui, et al.
Published: (2025-07-01) -
Expression of Concern: PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells
Published: (2020-01-01) -
RETRACTED ARTICLE: PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells
by: Junqiang Guo, et al.
Published: (2020-01-01)